Vertex Reports First Quarter 2024 Financial Results First Quarter 2024 Results Product revenue increased 13% to $2.69 billion compared to the first quarter of 2023, primarily driven in ex- U.S. markets by the continued strong uptake of TRIKAFTA /KAFTRIO , including label extensions in younger age groups, and in the U.S. by the continued performance of TRIKAFTA, including the uptake in children with CF 2 to 5 years of age. Net product revenue in the first quarter of 2024 increased 8% to $1.52 billion in the ...

Wall Street analysts expect Vertex Pharmaceuticals (VRTX) to post quarterly earnings of $4.10 per share in its upcoming report, which indicates a year-over-year increase of 34.4%. Revenues are expected to be $2.56 billion, up 7.8% from the year-ago quarter.The current level reflects an upward revision of 0.4% in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.Befor ...

Vertex Pharmaceuticals (VRTX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.Shares of this drugmaker have returned -4.1% over the past month versus the Zacks S&P 500 composite's -4.1% change. The Zacks Medical - Biomedical and Genetics industry, to which Vertex belongs, has lost 10.7% over this period. Now the key question is: Where could the stock be headed in t ...

Vertex Pharmaceuticals (VRTX) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended March 2024. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The earnings report, which is expected to be released on May 6, 2024, might help the stock move higher if these key numbers are better ...

•  Vertex erhält eine exklusive Lizenz für TreeFrogs C-Stem™ Herstellungstechnologie bei Typ-1-Diabetes •  TreeFrog und Vertex arbeiten gemeinsam an der Weiterentwicklung von vollständig differenzierten, Insulin produzierenden Inselzellen der Bauchspeicheldrüse BOSTON und BORDEAUX, Frankreich, 24. April 2024 /PRNewswire/ -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) und TreeFrog Therapeutics gaben heute bekannt, dass Vertex eine exklusive Lizenz für TreeFrogs firmeneigene Zellherstellungstechnologie ...

Vertex Pharmaceuticals Incorporated (VRTX) announced that it has entered into a licensing and collaboration agreement with France-based biotech company, TreeFrog Therapeutics, to optimize the production of VRTX's type 1 diabetes (T1D) cell therapies.The agreement will grant the pharmaceutical company an exclusive license to TreeFrog's proprietary cell manufacturing technology, C-Stem, which will be leveraged by VRTX to enhance its ability to generate large amounts of fully differentiated insulin-producing p ...

Vertex obtains an exclusive license to TreeFrog's C-StemTM  manufacturing technology in type 1 diabetes  TreeFrog and Vertex to collaborate on scale-up of fully differentiated, insulin-producing pancreatic islet cells  BOSTON and BORDEAUX, France, April 23, 2024 /PRNewswire/ -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and TreeFrog Therapeutics today announced that Vertex has obtained an exclusive license to TreeFrog's proprietary cell manufacturing technology, C-StemTM, to optimize production of ...

Could Vertex's growth story continue?Vertex Pharmaceuticals (VRTX 0.20%) has been through some ups and downs over the past few years. The big biotech disappointed investors when a couple of candidates outside of its specialty area of cystic fibrosis (CF) failed along the development path. But the company continued to impress with its CF products and their revenue growth as well as its advancement of other non-CF candidates in the pipeline.If you'd invested $10,000 in Vertex five years ago, you would have ac ...

Vertex Pharmaceuticals Incorporated (VRTX) announced that the FDA has granted a rolling new drug application (NDA) submission for suzetrigine (formerly known as VX-548) in moderate-to-severe acute pain. The company has already initiated the rolling submission process and is on track to complete the NDA submission in the second quarter of 2024.Suzetrigine is an investigational orally administered selective NaV1.8 pain signal inhibitor. The rolling NDA submission is supported by encouraging results from the c ...

The most recent trading session ended with Vertex Pharmaceuticals (VRTX) standing at $394.17, reflecting a -0.8% shift from the previouse trading day's closing. The stock fell short of the S&P 500, which registered a gain of 0.03% for the day. Elsewhere, the Dow gained 0.41%, while the tech-heavy Nasdaq added 0.12%.The drugmaker's stock has dropped by 3.41% in the past month, exceeding the Medical sector's loss of 5.81% and lagging the S&P 500's loss of 0.9%.Investors will be eagerly watching for the perfor ...